Numinus Offers Ketamine-Assisted Therapy in Toronto

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic therapies, today announced that its Toronto clinic, the Neurology Centre of Toronto (NCT) by Numinus, is now offering ketamine-assisted therapy for patients with neurologic conditions.

Dr. Evan Lewis (MD), VP, Psychedelic Neurology commented:

“Following a thorough evaluation, Numinus found NCT’s existing infrastructure, client base and practitioners to be highly suitable for offering ketamine-assisted therapy. Mental health challenges are commonly associated with neurologic diagnoses and ketamine-assisted therapy is a promising tool that we now have available for our patients.  The use of ketamine-assisted therapy within the field of neurology is novel, and we look forward to expanding access for our patients and contributing to the body of knowledge regarding ketamine applications.”

NCT focuses on conditions including epilepsy, concussion, brain injury and functional neurological disorders, offering a comprehensive range of services that include primary neurologic care and supportive therapies offered by a team of over 20 specialists.  The new service will be led by a psychologist and follow Numinus’ existing protocol for ketamine-assisted therapy, already in use in its other locations in Canada and the US, which includes sessions for medical screening, medicine dosing and therapy for integration.  The protocol will be modified to ensure it is appropriate for patients with neurological conditions.

A group of existing patients have been reviewed as candidates, with plans to provide treatment to more patients following evaluation of the initial cohort.

In addition to ketamine-assisted therapy.  NCT is expanding its capabilities to support applications for other psychedelic-assisted therapies through Health Canada Special Access Program (SAP).  The SAP is a federal program through which patients with demonstrable need can apply for access to investigational medical treatments that are not yet available to the public, including therapies using psychedelics such as MDMA and psilocybin.  A successful SAP application was recently completed by a Montreal Numinus physician to provide psilocybin-assisted therapy depression.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Notify of

Inline Feedbacks
View all comments